Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 5 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Introduction | 10 | 12 |
| Epidemiology | 10 | 1 |
| Symptoms | 10 | 1 |
| Etiology | 11 | 1 |
| Pathophysiology | 11 | 1 |
| Co-morbidities and Complications | 12 | 1 |
| Classification | 13 | 1 |
| Prognosis | 14 | 1 |
| Diagnosis | 14 | 2 |
| Assessing Treatment Effectiveness | 16 | 1 |
| Treatment Algorithm | 16 | 2 |
| The Role of Insulin in Type 2 Diabetes | 18 | 1 |
| Non-insulin Diabetic Drugs | 19 | 1 |
| Biguanides | 19 | 1 |
| Glucagon-Like Peptide-1 Agonists and DPP-4 Inhibitors | 19 | 1 |
| Sulfonylureas | 20 | 1 |
| Sodium-Dependent Glucose Transporter Inhibitors | 20 | 1 |
| Thiazolidinediones | 21 | 1 |
| Other Drugs | 21 | 1 |
| Alpha-Glucosidase (Maltase) Inhibitors | 21 | 1 |
| Bile Acid Sequestrants | 21 | 1 |
| Key Marketed Products | 22 | 19 |
| Metformin | 22 | 1 |
| DPP-4 Inhibitors | 23 | 1 |
| Januvia (sitagliptin) Merck &Co | 23 | 1 |
| Tradjenta (linagliptin) Boehringer Ingelheim | 24 | 1 |
| Onglyza (saxagliptin) Bristol-Myers Squibb and AstraZeneca | 25 | 1 |
| Nesina (alogliptin) Takeda | 25 | 1 |
| Galvus (vildagliptin) Novartis | 26 | 1 |
| Tenelia (teneligliptin) Daiichi Sankyo and Mitsubishi Tanabe | 27 | 1 |
| GLP-1 Agonists | 28 | 1 |
| Byetta and Bydureon (exenatide) Bristol-Myers Squibb | 28 | 1 |
| Lyxumia (lixisenatide) Sanofi | 29 | 1 |
| Victoza (liraglutide) Novo Nordisk | 30 | 1 |
| Sulfonylureas | 31 | 1 |
| Glimepiride | 31 | 1 |
| Gliclazide | 31 | 1 |
| Thiazolidinediones | 32 | 1 |
| Actos (pioglitazone) Takeda Pharmaceuticals Limited | 32 | 1 |
| Avandia (rosiglitazone) GlaxoSmithKline | 33 | 1 |
| Long-Acting Insulins | 34 | 1 |
| Lantus (insulin glargine) Sanofi | 34 | 1 |
| Levemir (insulin detemir) Novo Nordisk | 35 | 1 |
| Tresiba and Ryzodeg (Insulin degludec) Novo Nordisk | 36 | 1 |
| SGLT-2 Inhibitors | 37 | 1 |
| Forxiga (dapagliflozin) Bristol-Myers Squibb | 37 | 1 |
| Invokana (canagliflozin) Janssen | 37 | 1 |
| Heat Map for Marketed Products | 38 | 3 |
| Pipeline for Type 2 Diabetes | 41 | 23 |
| Overall Pipeline | 41 | 1 |
| Therapeutic Classes | 42 | 2 |
| Rate of Attrition | 44 | 1 |
| Failure Rate by Molecule Type | 44 | 1 |
| Failure Rate by Therapeutic Class | 45 | 3 |
| Reasons for Failure of Developmental Programs | 48 | 1 |
| Clinical Trial Duration | 48 | 1 |
| Duration by Molecule Type | 48 | 1 |
| Duration by Therapeutic Class | 49 | 2 |
| Clinical Trial Size | 51 | 1 |
| Clinical Trial Size by Molecule Type | 52 | 1 |
| Clinical Trial Size by Therapeutic Class | 53 | 2 |
| Promising Drugs in the Pipeline | 55 | 1 |
| LY-2189265 (dulaglutide) Eli Lilly | 55 | 1 |
| Albiglutide GlaxoSmithKline | 55 | 1 |
| LC15-044 (gemigliptin) LG Life Sciences | 56 | 1 |
| TAK-875 Takeda | 56 | 1 |
| Ipragliflozin Astellas Pharma | 57 | 1 |
| LX-4211 Lexicon Pharmaceuticals | 57 | 1 |
| Imeglimin Poxel SA | 58 | 1 |
| CCX-140-B ChemoCentryx | 58 | 1 |
| Semaglutide Novo Nordisk A/S | 59 | 1 |
| PC-DAC Exendin-4 ConjuChem Biotechnologies | 59 | 1 |
| Heat Map for Pipeline Products | 59 | 3 |
| Conclusion | 62 | 2 |
| Market Forecast to 2019 | 64 | 11 |
| Global Market | 64 | 1 |
| Treatment Usage Patterns | 64 | 1 |
| Market Size | 65 | 1 |
| US | 66 | 1 |
| Treatment Usage Patterns | 66 | 1 |
| Annual Cost of Therapy | 67 | 1 |
| Market Size | 67 | 1 |
| Top Five Countries of Europe | 68 | 1 |
| Treatment Usage Patterns | 68 | 1 |
| Annual Cost of Therapy | 69 | 1 |
| Market Size | 70 | 2 |
| Japan | 72 | 1 |
| Treatment Usage Patterns | 72 | 1 |
| Annual Cost of Therapy | 72 | 1 |
| Market Size | 73 | 1 |
| Drivers and Barriers | 73 | 1 |
| Drivers | 73 | 1 |
| Growing Prevalence of Type 2 Diabetes in Developed Nations | 73 | 1 |
| Anticipated Approval of Promising GLP-1 Agonists, SGLT Inhibitors and DPP-4 inhibitors Contribute to Diversity and Fuel Market Growth | 73 | 1 |
| Barriers | 74 | 1 |
| Widespread Usage of Sulfonylureas and Metformin | 74 | 1 |
| High Degree of Competition and Uncertain Overall Treatment Pattern | 74 | 1 |
| Deals and Strategic Consolidations | 75 | 14 |
| Licensing Deals | 75 | 3 |
| TransTech Pharma Enters into Licensing Agreement with Forest Laboratories | 78 | 1 |
| Xoma Enters into Licensing Agreement with Les Laboratoires Servier for Xoma 052 | 78 | 1 |
| Zealand Pharma Enters into a Licensing and Collaboration Agreement with Boehringer Ingelheim | 78 | 1 |
| Exelixis Enters into Licensing Agreement with Bristol-Myers Squibb for XL475 | 79 | 1 |
| Prosidion Limited Enters into a Licensing Agreement with Eli Lilly and Company | 79 | 1 |
| Metabolex Enters into Licensing Agreement with Sanofi | 79 | 1 |
| Wellstat Enters into a License Agreement with Sanofi | 79 | 1 |
| CureDM and Lankenau Institute Enter into a Licensing Agreement with Sanofi | 79 | 1 |
| Metabolex Enters into a Development and Licensing Agreement with Janssen Pharmaceuticals | 80 | 1 |
| Dainippon Sumitomo Pharma Enters into Licensing Agreement with Intercept Pharma for INT-747 | 80 | 1 |
| Ipsen Enters into Licensing Agreement with F. Hoffmann-La Roche for BIM 51077 | 80 | 1 |
| Glenmark Pharma Enters into Licensing Agreement with Merck KGaA | 80 | 1 |
| Euroscreen Enters into Licensing Agreement with Janssen Pharmaceuticals | 81 | 1 |
| Phenomix Enters into Licensing Agreement with Chiesi Farmaceutici | 81 | 1 |
| Otsuka Pharma Enters into Licensing Agreement with Kyowa Hakko Kirin for Saxagliptin | 81 | 1 |
| Nastech Pharma Enters into Licensing Agreement with Amylin Pharma | 81 | 1 |
| Emisphere Technologies Enters into a Licensing Agreement with Novo Nordisk | 81 | 1 |
| Array BioPharma Enters into a Licensing Agreement with Amgen | 82 | 1 |
| Theratechnologies Enters into a Licensing Agreement with OctoPlus | 82 | 1 |
| Diabetica Enters into a Licensing Agreement with Amylin | 82 | 1 |
| Celtic Therapeutics Enters into a Licensing Agreement with Bellus Health | 82 | 1 |
| Aradigm Enters into a Licensing Agreement with Novo Nordisk | 83 | 1 |
| Santarus Enters into a License Agreement with Shore Therapeutics | 83 | 1 |
| Depomed Enters into a Licensing Agreement with Boehringer Ingelheim | 83 | 1 |
| Depomed Enters into a Licensing Agreement with Merck | 83 | 1 |
| Depomed Enters into a Licensing Agreement with Teva | 84 | 1 |
| Co-development Deals | 84 | 1 |
| Eli Lilly Enters into a Co-development Agreement with Boehringer Ingelheim | 85 | 1 |
| AstraZeneca Enters into Co-development Agreement with Bristol-Myers Squibb | 86 | 1 |
| Metabolex Enters into a Co-development Agreement with Janssen Pharmaceuticals | 86 | 1 |
| Amylin Pharma Terminates Co-development Agreement with Eli Lilly for Exenatide | 86 | 1 |
| Isis Enters into a Collaboration Agreement with Janssen Pharmaceuticals | 86 | 1 |
| Neurocrine Biosciences Enters into a Collaboration Agreement with Boehringer Ingelheim | 87 | 1 |
| Intercept Pharma Enters into Co-development Agreement with Servier | 87 | 1 |
| Transition Therapeutics Enters into an Agreement with Eli Lilly | 87 | 1 |
| Ambrx Enters into a Co-Development Agreement with Bristol-Myers Squibb | 87 | 1 |
| Biocompatibles Enters into a Co-Development Agreement with AstraZeneca | 88 | 1 |
| Appendix | 89 | 35 |
| All Pipeline Drugs by Stage of Development | 89 | 16 |
| Discovery | 89 | 2 |
| Preclinical and IND-filed | 91 | 4 |
| Phase I | 95 | 3 |
| Phase II | 98 | 4 |
| Phase III and Pre-registration | 102 | 2 |
| Undisclosed | 104 | 1 |
| Market Forecasts to 2019 | 105 | 4 |
| Global | 105 | 1 |
| US | 105 | 1 |
| UK | 106 | 1 |
| France | 106 | 1 |
| Germany | 107 | 1 |
| Italy | 107 | 1 |
| Spain | 108 | 1 |
| Japan | 108 | 1 |
| Market Definitions | 109 | 1 |
| Abbreviations | 109 | 3 |
| References for Heat Maps | 112 | 2 |
| References | 114 | 5 |
| Research Methodology | 119 | 2 |
| Coverage | 119 | 1 |
| Secondary Research | 120 | 1 |
| Primary Research | 120 | 1 |
| Therapeutic Landscape | 121 | 1 |
| Epidemiology-based Forecasting | 121 | 1 |
| Market Size by Geography | 122 | 1 |
| Geographical Landscape | 123 | 1 |
| Pipeline Analysis | 123 | 1 |
| Expert Panel Validation | 123 | 1 |
| Contact Us | 123 | 1 |
| Disclaimer | 123 | 1 |